1. Reporting on the Prevalence of Antiretroviral Drug Resistance in a Regional HIV Population over 20 Years: A Word of Caution
- Author
-
Hartmut B. Krentz, Victoria C Gill, Soheil Ramazani, and Tarah Lynch
- Subjects
Adult ,Male ,0301 basic medicine ,Pediatrics ,medicine.medical_specialty ,Genes, Viral ,Genotype ,Anti-HIV Agents ,030106 microbiology ,Population ,Human immunodeficiency virus (HIV) ,HIV Infections ,Antiretroviral drug ,Resistance (psychoanalysis) ,medicine.disease_cause ,Alberta ,03 medical and health sciences ,Antiretroviral Therapy, Highly Active ,Drug Resistance, Viral ,Prevalence ,Humans ,Medicine ,Pharmacology (medical) ,Longitudinal Studies ,Viral suppression ,education ,Pharmacology ,education.field_of_study ,business.industry ,Middle Aged ,Viral Load ,Infectious Diseases ,Mutation ,HIV-1 ,Female ,business - Abstract
Background Failure to achieve complete viral suppression with antiretroviral drugs (ARV) may lead to uncontrolled HIV replication, ARV resistance and negative outcomes. Monitoring and reporting of HIV resistance trends is important but problematic. We examined prevalent resistance rates in an HIV population over 20 years and document how rates may appear to vary greatly based solely on which parameters are utilized. Methods We determined the annual use of geno-typic antiretroviral resistance testing (GART) from 1995 to 2014 for all patients receiving HIV care in southern Alberta, Canada, and the presence of resistance mutations in those tested. The impact on prevalent resistance rates of using cumulative or latest GART was also determined. Results Between 1995 and 2014, the number of patients with GART increased from Conclusions While prevalence resistance rates are decreasing, the precise rates being reported may vary due to increasing number of patients tested annually, using either the entire population as denominator or only patients with GART, and using either last or cumulative GART. Defining these parameters is critical if prevalence is to be compared over time or between HIV populations.
- Published
- 2016
- Full Text
- View/download PDF